We are the global leader in commercial manufacturing of specific
and non-specific IgY antibodies.

As the global leader in IgY Technology, we are actively developing Biologics, Consumer Health, and Animal Health solutions to address a wide range of needs.  Our development process integrates our clinical and operational teams to identify top tier prospects that we believe will have the most impact in the marketplace. We then work through a methodical development process to ensure the safety, effectiveness, and scalability of solutions.

Our core technology makes commercial health applications of IgY possible.

Our multi‐stage proprietary process allows for the environmentally friendly production of specific and non-specific IgY antibodies from hen egg yolks at high purities, high volumes and at low unit costs. This encourages adoption of IgY for health applications across nutraceutical, pharmaceutical, and animal health markets.

Manufacturing Capabilities

All products are manufactured in our purpose-built 10,000 square foot Health Canada and FDA registered, GMP accredited Canadian facility.  Our manufacturing provides the highest levels of quality control and batch traceability, combined with exceptional flexibility in meeting the needs of our customers whether they require large or small batch manufacturing.

MASON™ Manufacturing Process

Our patented proprietary MASON™ Manufacturing Process (MMP) is what makes us the leader in manufacturing commercial-scale IgY antibodies at an industry-leading purity of up to 99% pure IgY​.  MMP is environmentally friendly and allows us to return residual egg product back to the food industry for use in consumer food products.

Our Products

Non-Specific Antibodies

For Nutraceutical and Food Product Applications

Our raw, natural non-specific IgY antibodies are extracted from hens’ eggs using the MASON™ Technology to preserve their natural immune supporting characteristics. The extract is offered under our branded ingredient name, Muno-lgY™ to the nutraceutical and animal health markets.

Specific IgY Antibodies

For Biologics and Therapeutics Applications

Our pipeline consists of the development of biologic drugs and animal health solutions that address some the largest areas of clinical needs.  We apply the MASON™ Manufacturing Process to produce specific IgY antibodies up to 99% purity whether the product is to be classified as a nutraceutical or a biologic drug.